Trafalgar International (GCAN) Income from Continuing Operations (2017 - 2026)
Trafalgar International (GCAN) posted Income from Continuing Operations of -$33376.0 for Q1 2026, down 109.88% on a QoQ basis from $337757.0 in Q4 2025, and up 67.76% year-over-year from -$19895.6 in Q1 2025.
Powered by 
Analysis
Trafalgar International (GCAN) Income from Continuing Operations (2017 - 2026) Analysis & Trends
Trafalgar International has reported Income from Continuing Operations for 10 years, with the latest figure at -$33376.0 in Q1 2026.
- On a quarterly basis, Income from Continuing Operations rose 67.76% year-over-year to -$33376.0 in Q1 2026; TTM through Mar 2026 was -$122571.0, a 48.49% increase from a year earlier, with the FY2025 full-year figure at -$331612.0, down 85.22% from the prior year.
- Income from Continuing Operations was -$33376.0 for Q1 2026 at Trafalgar International, down from $337757.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was $337757.0 in Q4 2025, with the low at -$390853.0 in Q2 2025.
- Average Income from Continuing Operations over 5 years is -$56105.5, with a median of -$46165.0 recorded in 2024.
- The largest YoY upside for Income from Continuing Operations was 879.18% in 2025 against a maximum downside of 770.17% in 2025.
- Over 5 years, Income from Continuing Operations stood at -$47401.0 in 2022, then advanced by 1.14% to -$46861.0 in 2023, then gained by 7.5% to -$43348.0 in 2024, then jumped by 879.18% to $337757.0 in 2025, then plunged by 109.88% to -$33376.0 in 2026.
- The last three Income from Continuing Operations figures came in at -$33376.0 (Q1 2026), $337757.0 (Q4 2025), and -$36099.0 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 663.08 Bn | 642.33 Bn | 17.26 Bn | 5.53 Bn |
| 2 | AbbVie | 453.04 Bn | 446.51 Bn | 12.70 Bn | 3.62 Bn |
| 3 | Merck | 370.87 Bn | 363.78 Bn | 12.21 Bn | -1.34 Bn |
| 4 | Novartis Ag | 305.29 Bn | 298.00 Bn | 11.24 Bn | 5.28 Bn |
| 5 | Pfizer | 162.10 Bn | 150.70 Bn | 10.94 Bn | -246.00 Mn |
| 6 | Sanofi | 53.95 Bn | 46.98 Bn | 10.79 Bn | 2.16 Bn |
| 7 | Revolution Medicines | 45.00 Bn | 45.00 Bn | - | -644.37 Mn |
| 8 | Incyte | 25.47 Bn | 20.94 Bn | 1.57 Bn | 585.61 Mn |
| 9 | United Therapeutics | 20.81 Bn | 18.15 Bn | 683.80 Mn | 333.00 Mn |
| 10 | Trafalgar International | 217,335.05 | 217,335.05 | - | -33,376.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | -33,376.00 |
| Dec 31, 2025 | 337,757.00 |
| Sep 30, 2025 | -36,099.00 |
| Jun 30, 2025 | -390,853.00 |
| Mar 31, 2025 | -103,511.00 |
| Dec 31, 2024 | -43,348.00 |
| Sep 30, 2024 | -46,165.00 |
| Jun 30, 2024 | -44,917.00 |
| Mar 31, 2024 | -44,611.00 |
| Dec 31, 2023 | -46,861.00 |
| Sep 30, 2023 | -53,430.00 |
| Jun 30, 2023 | -45,043.00 |
| Mar 31, 2023 | -43,068.00 |
| Dec 31, 2022 | -47,401.00 |
| Sep 30, 2022 | -102,776.00 |
| Jun 30, 2022 | -62,405.00 |
| Mar 31, 2022 | -147,686.00 |
| Dec 31, 2021 | -196,331.00 |
| Sep 30, 2021 | -252,278.00 |
| Jun 30, 2021 | -38,964.00 |